Geron up after FDA accepts marketing application for blood disorder drug

Geron

21/08/2023 13:20

** Geron's shares  GERN.O  rise 4.6% to $2.73 before the
bell
    ** U.S. FDA accepts Geron's marketing application for its
drug to treat certain patients with transfusion-dependent anemia
    ** Application based on late-stage study data that showed
significantly higher transfusion independence in patients
treated with the drug vs a placebo
    ** GERN expects to submit EU marketing application in Q4
2023
    ** Up to Friday's close, stock had risen ~8% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))